ÂÜÀòÂÒÂ×

Sheila Annie Peters is an accomplished professional with extensive experience in quantitative pharmacology and modeling. Currently serving as the Executive Director and Early Asset Lead at Boehringer Ingelheim since November 2021 and the Head of Translational Quantitative Pharmacology at both the Healthcare Business of Merck and Merck KGaA, Darmstadt, Germany since September 2015, Sheila has been instrumental in developing teams of modeling and simulation experts and providing internal training in translational sciences. Prior experience includes a role as Associate Principal Scientist at AstraZeneca R&D, where Sheila contributed to lead optimization projects, and as Principal Scientist at Cyprotex, focused on developing ADME models. An academic background includes positions as Senior Lecturer at REC, Lecturer at Pondicherry University, and Lecturer at Auxilium College. Sheila holds a PhD in Theoretical and Computational Chemistry from the Indian Institute of Technology, Madras, along with an MSc and BSc in Chemistry from Loyola College and Stella Maris College, respectively.